Insulin glargine/lixisenatide Disease Interactions
There are 7 disease interactions with insulin glargine / lixisenatide.
- Angioedema
- Gastroparesis
- Pancreatitis
- Renal/liver disease
- Hypokalemia
- Hypoglycemia
- End stage renal disease
Lixisenatide (applies to insulin glargine/lixisenatide) angioedema
Major Potential Hazard, Moderate plausibility. Applicable conditions: Anaphylaxis
The use of lixisenatide may result in cross-sensitivity in patients with a history of anaphylaxis reaction or angioedema to another GLP-1 receptor agonist. These patients should be informed of the risk of anaphylaxis when using lixisenatide. Close monitoring is recommended when prescribing lixisenatide to these patients.
References (1)
- (2016) "Product Information. Adlyxin (lixisenatide)." sanofi-aventis
Lixisenatide (applies to insulin glargine/lixisenatide) gastroparesis
Major Potential Hazard, Moderate plausibility.
Lixisenatide slows gastric emptying and patients with preexisting gastroparesis were excluded from clinical trials. Lixisenatide should not be used in patients with severe gastroparesis.
References (1)
- (2016) "Product Information. Adlyxin (lixisenatide)." sanofi-aventis
Lixisenatide (applies to insulin glargine/lixisenatide) pancreatitis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Cholelithiasis, Alcoholism
Acute pancreatitis, including fatal and non- fatal hemorrhagic or necrotizing pancreatitis, has been reported postmarketing in patients treated with lixisenatide. Some patients had risk factors such as cholelithiasis and alcohol abuse. Patients should be observed carefully for any symptoms of pancreatitis including persistent abdominal pain, sometimes radiating to the back, that may or may not be accompanied by vomiting. If pancreatitis is suspected, lixisenatide should be discontinued and appropriate management should be established. If pancreatitis is confirmed, lixisenatide should not be restarted. Lixisenatide is not recommended for patients with history of pancreatitis.
References (1)
- (2016) "Product Information. Adlyxin (lixisenatide)." sanofi-aventis
Insulin (applies to insulin glargine/lixisenatide) renal/liver disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis. Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.
References (7)
- "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
- (2001) "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals
- (2022) "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc
- (2004) "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals
- (2005) "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc
- (2014) "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation
- (2015) "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc
Insulin- hypokalemia
Moderate Potential Hazard, Moderate plausibility.
Hypokalemia may commonly occur during treatment with insulin. Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).
References (7)
- "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
- (2001) "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals
- (2022) "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc
- (2004) "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals
- (2005) "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc
- (2014) "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation
- (2015) "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc
Insulin/oral hypoglycemic agents (applies to insulin glargine/lixisenatide) hypoglycemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Insufficiency, Malnourished, Autonomic Neuropathy, Panhypopituitarism, Anorexia/Feeding Problems
Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents. Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.
References (16)
- (2002) "Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals
- (2002) "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals
- "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
- (2002) "Product Information. Micronase (glyburide)." Pharmacia and Upjohn
- "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
- (2001) "Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel
- (2001) "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc
- (2001) "Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn
- (2001) "Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company
- (2001) "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals
- (2022) "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc
- (2001) "Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals
- (2004) "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals
- (2005) "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc
- (2015) "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc
- (2018) "Product Information. Glucophage (metFORMIN)." EMD Serono Inc, SUPPL-34
Lixisenatide (applies to insulin glargine/lixisenatide) end stage renal disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Acute kidney injury and worsening of chronic renal failure which sometimes required hemodialysis has been reported postmarketing in patients treated with lixisenatide. Renal function should be closely monitored when initiating or escalating doses. Lixisenatide is not recommended for patients with end stage renal disease. Patients with mild and moderate renal impairment need close monitoring but no dose adjustment. There is limited experience in patients with severe renal impairment but drug exposure showed to be higher, so close monitoring is recommended for changes in renal function or gastrointestinal adverse reactions.
References (1)
- (2016) "Product Information. Adlyxin (lixisenatide)." sanofi-aventis
Switch to consumer interaction data
Insulin glargine/lixisenatide drug interactions
There are 426 drug interactions with insulin glargine / lixisenatide.
Insulin glargine/lixisenatide alcohol/food interactions
There are 2 alcohol/food interactions with insulin glargine / lixisenatide.
More about insulin glargine / lixisenatide
- insulin glargine/lixisenatide consumer information
- Check interactions
- Compare alternatives
- Reviews (17)
- Side effects
- Dosage information
- During pregnancy
- Drug class: antidiabetic combinations
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.